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Abstract 
Background: Human Immunodeficiency Virus (HIV) and antiretroviral therapy (ART) are found to be 
strongly associated with cardiovascular diseases. Data are sparse on the prevalence and distribution of 
cardiovascular risk factors among people being treated for HIV in South Asia region. 
Methods: A cross-sectional study of 103 HIV patients (51 women and 52 men) attending routine follow-up 
consultations at the largest ART centre in Nepal was conducted. Data on several cardiovascular risk factors 
were collected through interview questionnaires, biophysical measurements and consulting medical records. 
Results: The most common cardiovascular risk factors observed were central obesity [34.6%, 95% 
Confidence Interval (CI): 25.3% to 43.9%], chronic kidney disease [20.7% (95% CI: 11.6% to 29.7%)] and 
tachycardia [20.6% (95% CI: 12.7% to 28.5%)]. Females were significantly more likely to have central 
obesity (male 9.8% vs. female 60%, p=0.016) and chronic kidney disease (male 15.4% vs. female 26.3%, 
p=0.003) as compared to the males. Participants were fairly active but a large proportion, especially men, 
had smoked [65% (95% CI: 57%-72.3%)], used tobacco products [66% (95% CI: 56.4%-74.4%)] or drugs 
(53.8% of the men) and consumed alcohol [60.2% (95% CI: 50.5%-69.1%)]. 
Conclusion: A high prevalence of several cardiovascular risk factors was observed among patients being 
treated for HIV in Nepal. Further larger studies are warranted to better understand the relevance and public 
health impact of cardiovascular risk factors in this region. 
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Introduction 
Antiretroviral therapy (ART) has rendered dramatic 
improvements in the life span and quality of life in 
patients infected with the Human Immunodeficiency 
Virus (HIV). However, several health risks and side-
effects are found to be strongly associated with HIV 
and/or the use of ART [1,2], including cardiovascular-
related complications [3]. A number of observational 
studies have suggested that patients being treated for 
HIV are at elevated risk of cardiovascular diseases (CVD) 
[3,4,5]. Much of this elevated risk is thought to be 
mediated by dyslipidemia, clinical lipodystrophy, central 
obesity, insulin resistance, hypertension and kidney 
diseases [6,7]. Furthermore, lifestyle choices which 
increase cardiovascular risk, such as tobacco usage, 
unhealthy diets, physical inactivity and drug abuse, are 
frequently observed among people living with HIV [8-
12]. 
The vast majority of previous studies of CVD among 
people with HIV were based in European, American and 
African settings, making it difficult to extrapolate 
findings to South Asia (which has distinct cultural, 
medical and lifestyle practices from other regions). Such 
lack of data from South Asia is in spite of rapid increases 
in the burden of CVD in the region [13], coupled with 
rapid increases in the usage of HIV treatments (reported 
to have increased 10 fold in the region in the past five 
years) [14]. 
Nepal is a developing South Asian country with a 
population of 30 million. Over 70,000 Nepalese people 
were living with HIV and AIDS in 2008 [15]. Since the 
inception of ART services in Nepal in 2004, the number 
of HIV patients on ART has increased 60 fold in five 
years with 3834 Nepalese reported to be on ART in 2010 
[16]. Likewise, a high prevalence of cardiovascular-
related risk factors (CVRF), mainly central obesity [17], 
hypertension [18], CKD [19], smokers and drinkers [20] 
were observed in the general Nepalese population. With 
the backdrop of the increasing rate of CVD in Nepal 
[21], a high prevalence of CVRF and improved access to 
ART, the aim of this study was to assess the prevalence 
and distribution of selected CVRF among patients being 
treated for HIV in Nepal. 
Methods 
Study Design: A cross-sectional study was conducted 
with non-randomly selected HIV infected patients 
receiving ARV medication and sequentially attending the 
routine follow up consultation at the Teku ART centre, 
Kathmandu, Nepal. This centre is the largest referral 
ART clinic in Nepal treating more than 800 HIV infected 
patients [22]. Ethical approval was obtained from the 
Nepal Health Research Council (NHRC) as per the 
guidelines of the University of Aberdeen college ethics 
review board. 
A total of 103 HIV patients were enrolled during the 
study period (11 April, 2010-10 May, 2010). HIV patients 
aged 25 or above, currently receiving ART and those 
who could understand and speak Nepalese were 
included in the study. HIV patients on ART but 
hospitalized and/or critically ill, with hearing and 
(Continued on page 24) 
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speaking disabilities, pregnant and who failed to give 
written informed consent were excluded. 
Data was collected by the researcher and trained 
research assistants using standardised operating 
protocols in conducting interview questionnaires, bio-
physical measurements and retrieving medical records.  
Interview Questionnaire: The questionnaire was adapted 
from previously validated questionnaires [23,24]. 
Questions were modified to the Nepalese context and 
culture, and face validity was tested by piloting among 
six volunteers. The accuracy of the English-Nepalese 
translation was checked by back-translation by a local 
Nepalese journalist and reviewed by bilingual research 
team members. The questionnaire included six sections 
comprising questions on demographics and socio-
economic information, physical activity, alcohol 
consumption, tobacco use/addiction, medical/medication 
history and dietary habits.  
For demographics and socio-economic information, data 
was collected on age, gender, ethnicity, education, 
occupation and income. The physical activity section 
included questions on physical activities at work and 
during leisure time, and total walking duration per day. 
For alcohol consumption information, data was collected 
on drinking status (current, past, never) as well as 
frequency, amount and type of alcohol use. Data on 
tobacco use and addiction was focussed on status of 
tobacco and smoking usage (current, past, never), types 
and duration of tobacco products use, number of 
cigarettes and other tobacco products consumed each 
day, second hand smoking, addiction status (current, 
past, never) and types of addiction. Dietary information 
was collected on the amount and frequency of fruit and 
vegetable; salt; fats and oils; dairy, meat, poultry, meat 
and fish products intake per day. The salt use was 
stratified into three groups of ‘low’, ‘moderate’, and 
‘high’ according to what the respondents reported using 
while cooking food. 
For the data on medical/medication history, questions 
included participants’ own and family history of  major 
CVDs and its risk factors as diagnosed by the doctor. 
Also, history of any medications for particular CVDs and 
its risk factors was recorded. 
Physiological Measurements: Body weight, height, hip 
and waist circumferences were measured using the 
World Health Organisation (WHO) standard protocols 
[25]. Blood pressure (BP) and heart rate (HR) were 
measured by the oscillometric method using digital 
automatic BP measuring devices (OMRON M2 HEM-7117
-E, OMRON Health Care Co. Ltd., Kyoto, Japan). BP and 
HR were taken at the seated position in a chair with feet 
on the floor and back straight. At the start and midpoint 
of the study, the reliability of these devices was verified 
with each other and with the blood pressure measuring 
machine used by clinical staff at the Teku ART centre. 
All bio-physical measurements were recorded twice and 
the average was considered for analysis. In the case of 
BP and HR, it was ensured that the second 
measurement was at least 10 minutes after the first one. 
Medical Records Retrieval: Selected biochemical values 
(White Blood Cell (WBC), lymphocytes, platelets, CD4+, 
serum creatinine), HIV medical history (mode of HIV 
transmission, date of HIV diagnosis and ART initiation) 
and HIV medication history (type and doses of 
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medication) were accessed from the Teku ART centre 
medical records (such data was retrievable for all 
participants). 
Definitions and Preferred Cut-off Values: Body mass 
index (BMI) was calculated as the ratio of weight to 
height squared (kg/m2). Waist to Hip (W-H) ratio was 
determined as waist circumference (cm) divided by hip 
circumference (cm). Obesity and overweight were 
classified using the redefined cut points for Asia-Pacific 
(obesity: BMI≥25kg/m2 and overweight: ≥23kg/m2), as 
per the guidelines of the International Diabetes Institute 
[27]. Central obesity was classified according to the 
WHO report on obesity 1997 (W-H ratio of 0.85 for 
women and 1.0 for men) [28]. Hypertension was 
defined according to the 1999 World Health Organisation
-International Society for Hypertension (WHO-ISH) 
guidelines, that is, systolic BP≥140mmHg and/or 
diastolic BP≥90mmHg [26]. Tachycardia was defined 
according to the established cut point - HR >100 b/m. 
Chronic kidney disease (CKD) was defined according to 
the guidelines of the American National Kidney 
Foundation [29], which is eGFR<60 ml/min/1.73 m2. 
eGFR was calculated using the Cockcroft-Gault formula 
[30]. 
Statistical Analysis: The statistical analysis was carried 
out using the IBM SPSS 20 package. Prevalence rates 
were presented in percentages, separately for males and 
females. Independent T test, Mann Whitney test and Chi
-squared test methods were employed to assess 
bivariate relationships at 0.05 significance level. 
 
Results 
A total of 103 participants was included in this study, of 
whom 52 (50.5%) were men and 51 (49.5%) women 
from a variety of ethnic groups (Table 1). The median 
age of men and women was 38 years (interquartile 
range [IQR] 33,42), and 34 years (IQR 32, 39.5) 
respectively. Most of the participants were living in an 
urban area (64.0%), 16.5% were unemployed and 
56.9% of the women and 15.4% of men had never 
attended school. 
The median duration of HIV positive status and ART use 
was nearly two-fold in women as compared to men 
(Table 1). The median duration of HIV positive status 
was 24 months (IQR 3.5, 42.5) in women, but among 
men it was 12 months (IQR 3.7, 41.2). Women 
participants were receiving ART for 11 median months 
(IQR 1, 31.2), as compared to the six months (IQR 1, 
32) for men. The median CD4+ count was 177 cells/
mm3 (IQR 84.25, 260.25) in men, however it was 
slightly higher among women at 213.5 cells/mm3 (IQR 
133.5, 348.5). 
Regarding lifestyle factors, 66% (95% CI: 56.8% to 
75.1%) of the participants had ever used tobacco 
products, 65% (95% CI: 55.7% to 74.3%) had ever 
smoked and 60.2% (95% CI: 50.7% to 69.6%) had ever 
consumed alcohol (Table 1). All of these three factors 
were extremely prevalent in males, and the differences 
in the proportion between males and females were 
statistically highly significant at <0.001 significance 
level. As regards relevant dietary intake in terms of 
(Continued on page 28) 
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Table 1: Socio-demographic and lifestyle characteristics and medical history of Nepalese HIV+ 
patients (N=103) 
Characteristics Men Women Total (%) 
Demographic Variables       
Gender (%) 52 (50.5) 51 (49.5) 103 (100) 
Ethnicity (%)       
 Brahmin/Chhetri 23 (44.2) 22 (43.1) 45 (43.7) 
 Tamang/Rai/Gurung/Magar 11 (21.1) 19 (37.2) 30 (29.1) 
 Newar 8 (15.4) 3 (5.9) 11 (10.7) 
 Others 10 (19.2) 7 (13.7) 17 (16.5) 
Age (Years)        
 Median (IQR) 38 (33,42) 34 (32, 40) 35 (32,41) 
Currently living region (%)       
 Kathmandu valley 33 (63.5) 33 (64.7) 66 (64.0) 
 Highway districts 13 (25.0) 9 (17.6) 22 (21.4) 
 Hilly districts 6 (11.5) 9 (17.6) 15 (14.6) 
Socio-economic Variables       
Monthly Household Income* (%)       
 <NRs. 5000 11 (21.1) 16 (31.4) 27 (26.2) 
 NRs. 5000-10000 22 (42.3) 15 (29.4) 37 (36.0) 
 > NRs. 10000 8 (15.4) 3 (5.9) 11 (10.7) 
 Not known 4 (7.7) 5 (9.8) 9 (8.7) 
 Prefer not to answer 7 (13.5) 12 (23.5) 19 (18.4) 
Occupation (%)       
 Unemployed 10 (19.2) 7 (13.7) 17 (16.5) 
 Agriculture 8 (15.4) 8 (15.7) 16 (15.5) 
 Business 7 (13.5) 6 (11.8) 13 (12.6) 
 Service 11 (21.1) 1 (1.9) 12 (11.6) 
 Labour 7 (13.5) 4 (7.8) 11 (10.7) 
 Others 9 (17.3) 25 (49.0) 34 (33.0) 
Education (%)       
 Never attended school 8 (15.4) 29 (56.9) 37 (36.0) 
 School level 40 (76.9) 22 (43.1) 62 (60.2) 
 Certificate level 2 (3.8) 0 (0) 2 (1.9) 
 Undergraduate level 2 (3.8) 0 (0) 2 (1.9) 
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* £1  = Nepalese Rupees (NRs.) 130, as of 20th October 2011 
Lifestyle variables       
Total walking period/day (%)       
 <30 minutes 11 (21.1) 11 (21.6) 22 (21.4) 
 30-60 minutes 9 (17.3) 6 (11.8) 15 (14.6) 
 1-2 hours 18 (34.6) 21 (41.2) 39 (37.9) 
 > 2 hours 14 (26.9) 13 (25.5) 27 (26.2) 
Alcohol intake status (%)       
 Never 3 (5.8)        38 (74.5)      41 (39.8) 
 Past 43 (82.7)  12 (23.5)  55 (53.4) 
 Current 6 (11.5)  1 (2.0)  7 (6.8) 
Tobacco intake status (%)       
 Never 4 (7.7) 31 (60.8) 35 (34.0) 
 Past 13 (25) 7 (13.7) 20 (19.4) 
 Current 35 (67.3) 13 (25.5) 48 (46.6) 
Smoking status (%)       
 Never 4 (7.7) 32 (62.7) 36 (35) 
 Past 13 (25) 6 (11.8) 19 (18.4) 
 Current 35 (67.3) 13 (25.5) 48 (46.6) 
Drug use (%) 28 (53.8) 0 (0) 28 (27.2) 
Dietary intake (%)       
Fruit & veg consumption (n=101)       
 <5 portions/day 43 (86.0) 48 (94.1) 91 (90.0) 
 ≥ 5 portions/day 7 (14.0) 3 (5.9) 10 (9.9) 
Salt intake       
 High 15 (53.6) 13 (46.4) 28 (27.2) 
 Moderate 27 (45.0) 33 (55.0) 60 (58.2) 
 Low 10 (66.7) 5 (33.3) 15 (14.6) 
HIV history (%)       
Mode of HIV transmission (n=69)       
 Heterosexual route 19 (50.0) 29 (93.5) 48 (69.6) 
 Injecting drug use 18 (47.4) 1 (3.2) 19 (27.5) 
 Unknown 1 (2.6) 1 (3.2) 2 (2.9) 
HIV diagnosis period (months) (n=83)       
 Median (IQR) 12 (3.7, 41.2) 24 (3.5, 42.5) 16 (4, 41) 
ART uptake period (months) (n=89)       
 Median (IQR) 6 (1, 32) 11 (1, 31.2) 8 (1, 31.5) 
Biochemical measurements       
WBC (cells/µL) (n=89)       
 Median (IQR) 5300 (4250, 7400) 4675 (4025, 5975) 4900 (4100, 6700) 
CD4+ (cells/mm3) (n=92)       
 Median (IQR)   177 (84.25, 260.25) 213.5 (133.5, 348.5) 193 (129, 292.75) 
eGFR (mL/min/1.73m2) (n=77)       
 Mean (SD) 86.28 (24.04) 78.59 (49.79) 82.49 (38.87) 
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cardiovascular risk, 88.3% (95% CI: 82.0% to 94.6%) 
of participants reported not attaining the recommended 
five portions of fruits and vegetables per day. Also, 
27.2% (95% CI: 18.6% to 35.8%) of participants 
reported a high salt intake. 
Prevalence of cardiovascular risk factors 
The most common CVRF observed were central obesity 
[34.6%, 95% Confidence Interval (CI) : 25.3% to 
43.9%],  CKD [20.7% (95% CI : 11.6% to 29.7%)] and 
tachycardia [20.6% (95% CI :12.7% to 28.5%)] (Figure 
1). Females were significantly more likely to have central 
obesity (male 9.8% vs. female 60%, p=0.016) and CKD 
(male 15.4% vs. female 26.3%, p=0.003) as compared 
to the males. Family history of CVD was reported by 
42.7% (95% CI: 33.1% to 52.2%) of the participants, 
and was significantly higher in males (male 57.7% vs. 
female 27.4%, p=0.004). Likewise, 8.7% (95% CI: 
3.3% to 14.2%) of the participants had a history of 
CVD, 3.9% (95% CI: 0.2% to 7.6%) reported being 
diagnosed with diabetes and 4.8% (95% CI : 0.7% to 
8.9%) were currently on medication for either CVD or 
hypertension or diabetes or in combination. 
We also examined the number of cardiovascular risk 
factors prevalent among the individual participants. For 
this analysis, we considered BMI, W-H ratio, heart rate, 
eGFR and hypertension (systolic or diastolic or both) as 
the risk factors. At least two CVRF  were concurrently 
prevalent among the 19.4% (95% CI: 12.9% to 28.2%) 
of the participants (Figure 2). Females were more likely 
to have ≥2 CVRF as compared to males (males 13.5% 
vs. females 25.5%), but this difference was statistically 
non-significant (p=0.196). 
 
CO: Central Obesity, CKD: Chronic Kidney Diseases, HT: Hypertension 
Figure 1: Prevalence of  CVD risk factors in the sample population.  
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Figure 2: Prevalence of  number of CVD risk factors in the sample population. 
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The association between CVRF and HIV drug groups was 
also assessed (Table 2), but no significant associations 
were observed. Most of the participants were on a 
combination of duovir and nevirapine drugs (52.4%), 
followed by duovir and efavirenz (15.5%), and 
lamivudine, stavudine and nevirapine (14.6%). 
Discussion 
This is the first study in Nepal to document CVRF among 
the HIV population on ART. The key findings of this 
study are a high prevalence of central obesity, CKD and 
tachycardia. Risky lifestyle habits such as a high 
prevalence of smoking and alcohol consumption, 
especially in males and poor dietary habits (low fruit and 
vegetable and high salt intake) were also found. Overall, 
a third (34.6%) of the participants had central obesity 
and females had a disproportionately higher prevalence 
(60.0%) than the males (9.8%). This corroborates 
findings in larger studies, where the prevalence of 
central adiposity among HIV patients on HAART was 
30% to 62% [31]. Falutz suggested that factors such as 
female gender and treatment with antiretroviral drugs 
zidovudine (AZT) and efavirenz (EFV) may contribute to 
raise the risk of central adiposity [32]. In our study, the 
vast majority of the participants (84.2%) were on AZT, 
EFV was also used by 24.2% and 17.9% were 
concurrently treated with both AZT and EFV along with 
other drug combinations. However, we could not 
demonstrate significant associations between HIV drug 
combinations and any of the CVRF. Due to the small 
sample size, we had to categorize nine drug 
combinations of the participants into two groups (duovir 
+ nevirapine and remaining combinations) for analysis. 
Very little research has been conducted in Nepal on 
central obesity based on W-H ratio and findings are 
hugely conflicting. In a study on healthy Nepalese 
males, central obesity was observed in 51.2% of the 
1000 participants [17]. By contrast, a recent study 
among 241 Nepalese men and women, found a 
prevalence of 2.5% in males and 10% in females [33]. 
The difference in cut-off values used to classify central 
obesity might have partly contributed to the difference 
in findings as Vaidya and colleagues [17] used a cut-off 
value of ≥0.95 for males and Adhikari and colleagues 
[35] did not mention the cut-off point. Geographical and 
cultural differences of the study sites may also have 
played role in the variation. Nonetheless, the finding of a 
higher prevalence of central obesity in females may 
underpin the notion that abdominal lipohypertrophy is 
predominant in HIV treated females [34], taking into 
consideration findings that South Asian populations, 
especially females, are more vulnerable to abdominal 
obesity [35]. This finding suggests the possible added 
risk of central obesity among HIV infected Nepalese 
females on ART. 
The CKD prevalence in this study (20.7%) was the 
highest compared to other Asian studies conducted on 
HIV infected patients on ART - A Japanese study found 
15.4% [36] and a Chinese study found 16.8% 
prevalence of CKD [37]. Notably, the prevalence found 
was also higher than in the general Nepalese population, 
where Sharma and colleagues reported CKD in 14.4% of 
8398 Nepalese adults [19]. The methodological 
differences in defining CKD though should be noted (this 
study estimated eGFR using a Cockcroft-Gault formula, 
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whereas Sharma and colleagues and the Chinese study 
followed the Modification of Diet in Renal Disease 
Equation (MDRD), and the Japanese study followed the 
equation suggested by Japanese Society of Nephrology). 
Among the antiretroviral agents, Tenofovir disoproxil 
fumerate (TDF) has been found to be associated with 
increased renal dysfunction [37], and the WHO has 
recognized it’s renal toxicity. However, in this study only 
two participants were being treated with TDF. This is an 
important factor for future studies as the use of TDF 
among the Nepalese HIV population is likely to increase 
rapidly in the future due to the recent guidelines of the 
WHO [38] which recommends the reduction of stavudine 
(d4T) and use of TDF in a first line regimen. Stavudine is 
currently the dominant HIV drug in the Nepalese HIV 
population. Thus, clinicians and researchers should be 
more aware of renal health of HIV treated patients in 
Nepal. 
Hypertension (systolic or diastolic) was found in 11.8% 
of the participants, which is significantly lower than the 
findings from other studies conducted in developed 
countries [39,40], but is similar to a study conducted in 
Africa (11.2%) [41]. It is interesting to note that the 
prevalence found is also lower than that of the general 
Nepalese population of 19.7% to 33.9% [18,42]. Several 
studies have demonstrated an association between 
hypertension and the duration of HAART. A large multi-
centered study suggested a significant association after 
two years on HAART [43], and an American study 
showed no association till six months [44]. In this study, 
the median duration of HAART use was eight months 
and could partly explain the lower rates. Larger studies 
are required to confirm the prevalence and aetiology of 
hypertension in the HIV treated Nepalese population.  
Findings suggest that health education should target 
certain lifestyle habits i.e. smoking, alcohol consumption, 
diet and physical activity within the HIV treated 
Nepalese population to decrease their CVRF. The 
prevalence of smoking in this study was higher than in 
the general Nepalese population (current smokers: 
46.6% vs. 23.8%) [20], but is consistent with findings 
among other HIV+ populations [3,45]. A propensity for 
smoking among people living with HIV could be due to 
its perceived role in emotional support and stress 
reduction [46]. Men especially should be targeted to 
educate them regarding the increased cardiovascular 
risk of smoking and other stress reduction therapies 
introduced. 
In contrast, a considerably lower prevalence of current 
alcohol consumption was reported in the HIV infected 
participants than in the general Nepalese community 
(6.9% vs. 28.5%) [20]. This is also in contradiction to 
common trends found in studies conducted in developed 
countries [10,47]. It is noteworthy that the prevalence 
of ever having consumed alcohol is higher though which 
could indicate that participants may have under-reported 
their alcohol consumption owing to social desirability 
bias or alternatively, due to the fact that two-thirds of 
the participants were poor, were not able to afford the 
high cost of alcohol. Alternatively, health education may 
have targeted this and resulted in a change in alcohol 
consumption habits. 
As this was a cross-sectional study, a cause-effect 
relationship between CVRF and ART cannot be inferred. 
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As participants were non-randomly selected and all 
based at one ART centre, the results shouldn’t be 
extrapolated to Nepal as a whole. Further limitations of 
self-reported responses could have introduced bias and 
restricted recorded biochemical measurements resulted 
in not being able to investigate the prevalence of other 
CVRF such as dyslipidaemia, clinical lipodystrophy and 
diabetes mellitus. 
Although this was a cross-sectional study on a small 
sample, it provides important insights on the apparent 
risk of CVRF among HIV infected Nepalese patients on 
ART and warrants the need for further prospective and 
longitudinal studies. 
 
Conclusion and Recommendations 
This study provides important insights on the prevalence 
of CVRF among HIV infected Nepalese patients on ART, 
finding a high prevalence of central obesity, CKD and 
tachycardia as well as risky lifestyle habits. Not only 
does this warrant the need for further prospective and 
longitudinal studies, but it has implications for treatment 
and intervention within this population group. It also 
seems that health education messages should be gender
-specific, with women being targeted with messages to 
avoid the risk of abdominal obesity and men regarding 
smoking and alcohol consumption as well as stress 
reduction therapy provided. Both groups should be 
educated about following a healthy diet and encouraged 
to continue doing physical activity. Finally, renal function 
should be monitored more closely if WHO guidelines are 
followed and TDF used more widely. 
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